Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 866 results for score

  1. Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in under 16s (not pregnant or recently pregnant). It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  2. Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)

    Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.

  3. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.

  4. Reasons for refusal for consent:- Why do families refuse to give permission for organ donation?

    donation have higher perceived benefits scores, lower prolonged grief scores and higher quality-of-life scores...

  5. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  6. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  7. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  8. Soft-palate implants for simple snoring (IPG240)

    Evidence-based recommendations on soft-palate implants for simple snoring. This involves inserting implants into the soft palate of the mouth to make it stiffer and less likely to vibrate.

  9. Axumin for functional imaging of prostate cancer recurrence (MIB172)

    NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .

  10. MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery (MIB323)

    NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .

  11. Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)

    Evidence-based recommendations on percutaneous cementoplasty for palliative treatment of bony malignancies. This involves injecting a special cement into the bone in order to stabilise it, reduce pain, or both.

  12. Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease (IPG222)

    Evidence-based recommendations on endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for gastro-oesophageal reflux. This involves inserting hydrogel implants into the wall of the oesophagus to narrow the entrance to the stomach and help prevent reflux.

  13. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

  14. Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)

    Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.

  15. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.